



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/765,644
Filing Date	January 23, 2001
First Named Inventor	Michal Elsey HACH-SCHWARTZ
Group Art Unit	1846 1647
Confirmation No.	6853
Attorney Docket Number	EIS-SCHWARTZ=13B

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant/Inventor of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant/Inventor of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
BBB	AA	WO	99/41247	—	WEINER et al	08-19-1999	—	—

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BBB	AB	Aharoni et al, "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", <u>Proc. Natl. Acad. Sci. USA</u> 94:10821-10826 (1997)	—
	AC	Aharoni et al "Cop-1 specific suppressor cells inhibit experimental allergic encephalomyelitis induced by either mouse spinal cord homogenate or proteolipid protein peptide 139-151", <u>Neurology Meeting Info.: 49th Ann. Meeting of the American Academy of Neurology</u> , Vol. 48, No. 3 (suppl. 2), page A422 XP 001029141 (1997) (abstract)	—
	AD	TEVA; YEDA; Hoechst Marion Roussel, "Copolymer-1, Glatiramer Acetate, Copaxone®: Agent for Multiple Sclerosis", <u>Drugs of the Future</u> , Vol. 23, No. 2 (1998)	—
BBB	AE	Edwards et al, "Peptides as drugs", <u>Q.J.M. Monthly Journal of the Association of Physicians</u> , Vol. 92, No. 1, pages 1-4, XP 001029184 (1999)	—

Examiner Signature	Bridget E. Bunner	Date Considered	4/9/03
-----------------------	-------------------	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.